Business
Currency:USD
2024/FY
Stock NameRevenueRatio
Developing and commercializing genetically engineered allogeneic T cell product candidates for the22K100.00%
Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States22K100.00%